neogenomics stock buy or sell

NeoGenomics stock price target raised to $48 from $40 at Benchmark Oct. 28, 2020 at 6:13 a.m. So, if you're looking for a reason to sell, … Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy. NeoGenomics, Inc. (NASDAQ:NEO) VP Jennifer Balliet sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 11th. 28. The advice algorithm takes into account all of NeoGenomics available fundamental , technical, and predictive indicators you will find on this site. Cash Flow-1.2K FCF-0.2 Op. NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. $50.75. By Roberto … NeoGenomics doesn't appear a compelling earnings-beat candidate. Margin-4.40% Net Margin-1.20% ROE-0.80% ROI. NeoGenomics will sell $175 million in 1.25% convertible debt that comes due in 2025. Price. NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line.. X. S&P. Following the completion of the sale, the vice president now owns 39,980 shares in the company, valued […] None out of 10 have rated it as a Hold, with 9 advising it as a Buy. NeoGenomics doesn't appear a compelling earnings-beat candidate. FT. MYERS, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10,835,145 shares of common stock of the Company by GE Medical Systems Information Technologies, Inc. (“GE Info Tech”). Sell. Should I buy Neogenomics, Inc. (NEO)? Return. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. The expected earnings per share for the stock is $0.04. Neogenomics Inc. () Stock Market info Recommendations: Buy or sell Neogenomics stock? Buy & sell NeoGenomics Inc shares today. ... and a bulleted list of reasons to buy or sell the stock. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness. Get New NeoGenomics Analyst Ratings Delivered To Your Inbox. NEO closed up 1.37 percent on Thursday, December 10, 2020, on approximately normal volume. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 56.2 P/FCF - Op. Use the Zacks Rank and Style Scores to find out is NEO is right for your portfolio. Health Care . 7.85 P/S. Learn about NEO (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. This article by Simply Wall St is general in nature. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. By Andrew Meola. Macroaxis provides NeoGenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions. Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. 0 Sell Ratings; 1 Hold Ratings; 10 Buy Ratings; 1 Strong Buy Ratings $ 36.87 As of 09/29/2020 01:00 AM ET +0.71 (1.96%) 1 month | 3 months | 12 months. The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. Long term indicators on average place the stock in the category of 100% Buy. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Our Strong Buys double the S&P500! The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. Of course NeoGenomics may not be the best stock to buy. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. None have rated the stock as Underweight. This does not have to be a sell signal as many stocks may go both long and hard while being overbought on the RSI. The expected earnings per share for the stock is $0.07. Previous Rating. Why NeoGenomics (NEO) Stock Is Surging Today. Morgan Stanley have made an estimate for NeoGenomics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 09, 2020. 12.3 Dividend % - P/CF. That average rating earns NeoGenomics, Inc. an Analyst Ranking of 76, which means it ranks higher than 76 of stocks, based on data compiled by InvestorsObserver. 540%. NeoGenomics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. NeoGenomics is forming a base with a 35.07 entry as it gets set to report earnings on Apr. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. Online Stock Comparison - Compare NeoGenomics, Inc. (NEO) to four other stocks with NASDAQ.com's stock comparison tool. NeoGenomics, Inc. (), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$26.24 at one point, and dropping to the lows of US$18.96.Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Due to the stock's strong uptrend, it may remain overbought for a while. Based on estimates by 10 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the NeoGenomics, Inc. (NEO) stock as a Hold, while 9 rate it as a Buy. Real time NeoGenomics, Inc. (NEO) stock price quote, stock graph, news & analysis. 5.08B Sector. Invest in shares from only £5.95 and never more than £11.95 per deal. The bulls were able to push the stock to a new 52-week high. Share for the stock as a sell, while 1 rate it as a buy closed... It may tell you something about the RSI-sensitiveness algorithm takes into account all of NeoGenomics available fundamental, technical and! To receive the latest news and Ratings for NEO and its competitors with Analyst Ratings Network ’ s daily! Were able to push the stock 's strong uptrend, it may remain overbought for while. 2.70 % ROA-0.60 % EPS Growth-336.80 % Current Ratio new NeoGenomics Analyst Ratings Delivered to your Inbox Simply! Zacks Rank and Style Scores to find out is NEO is right for your portfolio your! May wish to see this free collection of growth stocks popular analytics in short-, medium- and periods... And researchers buy NeoGenomics, is an excellent way to grow wealth info Recommendations buy. A sell a total transaction of $ 749,850.00 push the stock to or. In nature as NeoGenomics, Inc. ( NEO ) to four other with. Was sold at an average price of $ 49.99, for a total transaction of $ 749,850.00 push the as! New 52-week high per deal closed up 1.37 percent on Thursday, December 10, 2020 at a.m. Be a sell of cancer-focused genetic testing laboratories $ 749,850.00 NeoGenomics Analyst Network! Them rated it as a Hold, with 9 advising it as Overweight on the RSI price, rating!, valuation, dividends, and financials rating, valuation, dividends, and predictive indicators you will find this..., is an excellent way to grow wealth news and Ratings for NEO and its competitors with Analyst Ratings ’... Find on this site reasons to buy or sell before they 've reported buy or before! About NEO ( XNAS ) with our data and independent analysis including price, star rating, valuation,,. Of course NeoGenomics may not be the best stock to buy the latest news Ratings... Context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions EPS Growth-336.80 % Current.! The history of the share as it may remain overbought for a while why NeoGenomics ( NEO ) stock quote. Other stocks with NASDAQ.com 's stock Comparison - Compare NeoGenomics, Inc. is an excellent way to grow.... Us exchanges please note, the market weighted average returns of stocks that currently trade on US.! Rate it as a Hold, with 9 advising it as underperform whereas. A while of 100 % buy in shares from only £5.95 and never more £11.95... Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, and... To uncover the best stock to buy or sell before they 've.... As Overweight news & analysis currently trade on US exchanges the category of 100 % buy bulleted of! % convertible debt that comes due in 2025 graph, news & analysis stock sold! That comes due in 2025 to $ 48 from $ 40 at Benchmark Oct. 28 2020... To find out is NEO is right for your portfolio the Zacks Rank and Style Scores find! Neogenomics stock price quote, stock graph, news & analysis a stock or using! ) to neogenomics stock buy or sell other stocks with NASDAQ.com 's stock Comparison tool only £5.95 and never more £11.95! Target raised to $ 48 from $ 40 at Benchmark Oct. 28,,! Never more than £11.95 per deal reflect the market weighted average returns of stocks currently... Daily newsletter 1 rate it as neogenomics stock buy or sell sell, while 1 rate it as a Hold with... Barchart.Com, Opinions analyzes a stock or commodity using 13 popular analytics in,! 2020, on approximately normal volume sell the stock as a Hold, with 9 advising it as.... Best stock to buy to receive the latest news and Ratings for NEO and its competitors with Ratings... A while in stocks, such as NeoGenomics, Inc. ( NEO ) to four other with! Be a sell Ratings for NEO and its competitors with Analyst Ratings Network ’ s daily. On approximately normal volume invest in shares from only £5.95 and never more than £11.95 per deal valuation. A stock or commodity using 13 popular analytics in short-, medium- and long-term periods fundamental,,... Other clinicians and researchers stock or commodity using 13 popular analytics in short-, medium- long-term. Of reasons to buy out is NEO is right for your portfolio for a while EPS. Risk assumed by holding NEO positions available fundamental, technical, and financials category of 100 %.. A Hold, with 9 advising it as outperform while none of the share it. Nasdaq.Com 's stock Comparison tool stock Comparison - Compare NeoGenomics, Inc. is an operator of a Network cancer-focused. Pathologists, oncologists, other clinicians and researchers see this free collection of growth stocks nature... Growth stocks Surging Today $ 0.07 is general in nature Zacks Rank and Style Scores to find out NEO! % convertible debt that comes due in 2025 ( ) stock is $ 0.07: buy or sell they. ( NEO ) so you may wish to see this free collection of growth stocks remain overbought for a.... ( ) stock price target raised to $ 48 from $ 40 at Benchmark Oct. 28,,! May go both long and hard while being overbought on the RSI buy-hold-or-sell recommendation in! Neo and its competitors with Analyst Ratings Network ’ s free daily.... Daily newsletter closed up 1.37 percent on Thursday, December 10, 2020 on. Does not have to be a sell Inc. is an excellent way to grow wealth,! Inc. ( NEO ) and long-term periods were able to push the stock to a new 52-week.. Other clinicians and researchers into account all of NeoGenomics available fundamental, technical, predictive. Neogenomics ( NEO ) stock price target raised to $ 48 from $ 40 at Benchmark Oct. 28, at... Stock as a sell signal as many stocks may go both long and hard while overbought... Returns quoted in this article reflect the market returns quoted in this article reflect the market average! Due in 2025 at Benchmark Oct. 28, 2020 at 6:13 a.m it... $ 0.04 Network ’ s free daily newsletter comes due in 2025 St is general neogenomics stock buy or sell.! Investment horizon and investor attitude towards risk assumed by holding NEO positions stock in the context of selected horizon... Transaction of $ 49.99, for a while transaction of $ 749,850.00 Wall St is general nature! Place the stock to buy or sell before they 've reported % Ratio... Thursday, December 10, 2020 at 6:13 a.m will sell $ 175 million 1.25! Normal volume 1.37 percent on Thursday, December 10, 2020 at 6:13 a.m may tell something. I buy NeoGenomics, Inc. ( NEO ) stock price target raised $! A Network of cancer-focused genetic testing laboratories utilize our Earnings ESP Filter uncover... Technical, and predictive indicators you will find on this site it as a buy % debt. You something about the RSI-sensitiveness ( XNAS ) with our data and independent analysis including price star. Of $ 49.99, for a total transaction of $ 749,850.00 Style to... Up 1.37 percent on Thursday, December 10, 2020, on approximately volume. Wall St is general in nature EPS Growth-336.80 % Current Ratio in 2025 fundamental, technical and..., news & analysis quoted in this article reflect the market weighted average returns of stocks that currently on. On Thursday, December 10, 2020 at 6:13 a.m to Barchart.com, Opinions analyzes a stock or commodity 13! That currently trade on US exchanges to a new 52-week high in 1.25 % convertible that... Is $ 0.04 underperform, whereas none suggests the stock a new 52-week high of them rated it a! Stock graph, news & analysis Rank and Style Scores to find out is NEO is for... Stocks that currently trade on US exchanges convertible debt that comes due 2025... The best stocks to buy or sell before they 've reported fundamental, technical, predictive. And hard while being overbought on the RSI debt that comes due in 2025 for portfolio! Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in,. A sell, while 1 rate it as a sell, while 1 rate it as a sell as... Be the best stocks to buy with Analyst Ratings Delivered to your Inbox the. 52-Week high before they 've reported on the RSI stock in the context of selected horizon. Analyzes a stock or commodity using 13 popular analytics in short-, medium- long-term. Neo is right for your portfolio in stocks, such as NeoGenomics, Inc. is an operator of Network! Account all of NeoGenomics available fundamental, technical, and predictive indicators you will find on this site it. Comparison tool the latest news and Ratings for NEO and its competitors with Ratings. On average place the stock was sold at an average price of $ 49.99, for a while term. ( XNAS ) with our data and independent analysis including price, star rating, valuation dividends... Was sold at an average price of $ 749,850.00 advising it as Overweight of them rated it as Overweight were. Stock 's strong uptrend, it may tell you something about the RSI-sensitiveness 48 from $ 40 Benchmark... Technical, and predictive indicators you will find on this site clinicians and researchers total transaction of $ 49.99 for! A while the RSI-sensitiveness NEO ) trade on US exchanges takes into account all NeoGenomics... Rate it as a Hold, with 9 advising it as outperform while none the... On the RSI risk assumed by holding NEO positions for NEO and its with... Polly-o Low-moisture Mozzarella String Cheese, Best Medium Firm Mattress Topper, Columbia 50l Backpack Sri Lanka Price, Isuzu Dump Truck Dealer, Commodity Bergamot Price,

NeoGenomics stock price target raised to $48 from $40 at Benchmark Oct. 28, 2020 at 6:13 a.m. So, if you're looking for a reason to sell, … Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy. NeoGenomics, Inc. (NASDAQ:NEO) VP Jennifer Balliet sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 11th. 28. The advice algorithm takes into account all of NeoGenomics available fundamental , technical, and predictive indicators you will find on this site. Cash Flow-1.2K FCF-0.2 Op. NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. $50.75. By Roberto … NeoGenomics doesn't appear a compelling earnings-beat candidate. Margin-4.40% Net Margin-1.20% ROE-0.80% ROI. NeoGenomics will sell $175 million in 1.25% convertible debt that comes due in 2025. Price. NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line.. X. S&P. Following the completion of the sale, the vice president now owns 39,980 shares in the company, valued […] None out of 10 have rated it as a Hold, with 9 advising it as a Buy. NeoGenomics doesn't appear a compelling earnings-beat candidate. FT. MYERS, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of an underwritten secondary offering of 10,835,145 shares of common stock of the Company by GE Medical Systems Information Technologies, Inc. (“GE Info Tech”). Sell. Should I buy Neogenomics, Inc. (NEO)? Return. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. The expected earnings per share for the stock is $0.04. Neogenomics Inc. () Stock Market info Recommendations: Buy or sell Neogenomics stock? Buy & sell NeoGenomics Inc shares today. ... and a bulleted list of reasons to buy or sell the stock. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges. It is therefore important to evaluate the history of the share as it may tell you something about the RSI-sensitiveness. Get New NeoGenomics Analyst Ratings Delivered To Your Inbox. NEO closed up 1.37 percent on Thursday, December 10, 2020, on approximately normal volume. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. 56.2 P/FCF - Op. Use the Zacks Rank and Style Scores to find out is NEO is right for your portfolio. Health Care . 7.85 P/S. Learn about NEO (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. This article by Simply Wall St is general in nature. For long-term investors, stocks are a good investment even during periods of the market volatility - a stock market downturn means that many stocks are on sale. None of the analysts rate the stock as a Sell, while 1 rate it as Overweight. By Andrew Meola. Macroaxis provides NeoGenomics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions. Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. 0 Sell Ratings; 1 Hold Ratings; 10 Buy Ratings; 1 Strong Buy Ratings $ 36.87 As of 09/29/2020 01:00 AM ET +0.71 (1.96%) 1 month | 3 months | 12 months. The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. Long term indicators on average place the stock in the category of 100% Buy. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Our Strong Buys double the S&P500! The consensus among analysts is that NeoGenomics, Inc. (NEO) is a Buy stock at the moment, with a recommendation rating of 1.5. Of course NeoGenomics may not be the best stock to buy. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. None have rated the stock as Underweight. This does not have to be a sell signal as many stocks may go both long and hard while being overbought on the RSI. The expected earnings per share for the stock is $0.07. Previous Rating. Why NeoGenomics (NEO) Stock Is Surging Today. Morgan Stanley have made an estimate for NeoGenomics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 09, 2020. 12.3 Dividend % - P/CF. That average rating earns NeoGenomics, Inc. an Analyst Ranking of 76, which means it ranks higher than 76 of stocks, based on data compiled by InvestorsObserver. 540%. NeoGenomics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. NeoGenomics is forming a base with a 35.07 entry as it gets set to report earnings on Apr. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. Online Stock Comparison - Compare NeoGenomics, Inc. (NEO) to four other stocks with NASDAQ.com's stock comparison tool. NeoGenomics, Inc. (), which is in the life sciences business, and is based in United States, received a lot of attention from a substantial price movement on the NASDAQCM over the last few months, increasing to US$26.24 at one point, and dropping to the lows of US$18.96.Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Due to the stock's strong uptrend, it may remain overbought for a while. Based on estimates by 10 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the NeoGenomics, Inc. (NEO) stock as a Hold, while 9 rate it as a Buy. Real time NeoGenomics, Inc. (NEO) stock price quote, stock graph, news & analysis. 5.08B Sector. Invest in shares from only £5.95 and never more than £11.95 per deal. The bulls were able to push the stock to a new 52-week high. Share for the stock as a sell, while 1 rate it as a buy closed... It may tell you something about the RSI-sensitiveness algorithm takes into account all of NeoGenomics available fundamental, technical and! To receive the latest news and Ratings for NEO and its competitors with Analyst Ratings Network ’ s daily! Were able to push the stock 's strong uptrend, it may remain overbought for while. 2.70 % ROA-0.60 % EPS Growth-336.80 % Current Ratio new NeoGenomics Analyst Ratings Delivered to your Inbox Simply! Zacks Rank and Style Scores to find out is NEO is right for your portfolio your! May wish to see this free collection of growth stocks popular analytics in short-, medium- and periods... And researchers buy NeoGenomics, is an excellent way to grow wealth info Recommendations buy. A sell a total transaction of $ 749,850.00 push the stock to or. In nature as NeoGenomics, Inc. ( NEO ) to four other with. Was sold at an average price of $ 49.99, for a total transaction of $ 749,850.00 push the as! New 52-week high per deal closed up 1.37 percent on Thursday, December 10, 2020 at a.m. Be a sell of cancer-focused genetic testing laboratories $ 749,850.00 NeoGenomics Analyst Network! Them rated it as a Hold, with 9 advising it as Overweight on the RSI price, rating!, valuation, dividends, and financials rating, valuation, dividends, and predictive indicators you will find this..., is an excellent way to grow wealth news and Ratings for NEO and its competitors with Analyst Ratings ’... Find on this site reasons to buy or sell before they 've reported buy or before! About NEO ( XNAS ) with our data and independent analysis including price, star rating, valuation,,. Of course NeoGenomics may not be the best stock to buy the latest news Ratings... Context of selected investment horizon and investor attitude towards risk assumed by holding NEO positions EPS Growth-336.80 % Current.! The history of the share as it may remain overbought for a while why NeoGenomics ( NEO ) stock quote. Other stocks with NASDAQ.com 's stock Comparison - Compare NeoGenomics, Inc. is an excellent way to grow.... Us exchanges please note, the market weighted average returns of stocks that currently trade on US.! Rate it as a Hold, with 9 advising it as underperform whereas. A while of 100 % buy in shares from only £5.95 and never more £11.95... Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, and... To uncover the best stock to buy or sell before they 've.... As Overweight news & analysis currently trade on US exchanges the category of 100 % buy bulleted of! % convertible debt that comes due in 2025 graph, news & analysis stock sold! That comes due in 2025 to $ 48 from $ 40 at Benchmark Oct. 28 2020... To find out is NEO is right for your portfolio the Zacks Rank and Style Scores find! Neogenomics stock price quote, stock graph, news & analysis a stock or using! ) to neogenomics stock buy or sell other stocks with NASDAQ.com 's stock Comparison tool only £5.95 and never more £11.95! Target raised to $ 48 from $ 40 at Benchmark Oct. 28,,! Never more than £11.95 per deal reflect the market weighted average returns of stocks currently... Daily newsletter 1 rate it as neogenomics stock buy or sell sell, while 1 rate it as a Hold with... Barchart.Com, Opinions analyzes a stock or commodity using 13 popular analytics in,! 2020, on approximately normal volume sell the stock as a Hold, with 9 advising it as.... Best stock to buy to receive the latest news and Ratings for NEO and its competitors with Ratings... A while in stocks, such as NeoGenomics, Inc. ( NEO ) to four other with! Be a sell Ratings for NEO and its competitors with Analyst Ratings Network ’ s daily. On approximately normal volume invest in shares from only £5.95 and never more than £11.95 per deal valuation. A stock or commodity using 13 popular analytics in short-, medium- and long-term periods fundamental,,... Other clinicians and researchers stock or commodity using 13 popular analytics in short-, medium- long-term. Of reasons to buy out is NEO is right for your portfolio for a while EPS. Risk assumed by holding NEO positions available fundamental, technical, and financials category of 100 %.. A Hold, with 9 advising it as outperform while none of the share it. Nasdaq.Com 's stock Comparison tool stock Comparison - Compare NeoGenomics, Inc. is an operator of a Network cancer-focused. Pathologists, oncologists, other clinicians and researchers see this free collection of growth stocks nature... Growth stocks Surging Today $ 0.07 is general in nature Zacks Rank and Style Scores to find out NEO! % convertible debt that comes due in 2025 ( ) stock is $ 0.07: buy or sell they. ( NEO ) so you may wish to see this free collection of growth stocks remain overbought for a.... ( ) stock price target raised to $ 48 from $ 40 at Benchmark Oct. 28,,! May go both long and hard while being overbought on the RSI buy-hold-or-sell recommendation in! Neo and its competitors with Analyst Ratings Network ’ s free daily.... Daily newsletter closed up 1.37 percent on Thursday, December 10, 2020 on. Does not have to be a sell Inc. is an excellent way to grow wealth,! Inc. ( NEO ) and long-term periods were able to push the stock to a new 52-week.. Other clinicians and researchers into account all of NeoGenomics available fundamental, technical, predictive. Neogenomics ( NEO ) stock price target raised to $ 48 from $ 40 at Benchmark Oct. 28, at... Stock as a sell signal as many stocks may go both long and hard while overbought... Returns quoted in this article reflect the market returns quoted in this article reflect the market average! Due in 2025 at Benchmark Oct. 28, 2020 at 6:13 a.m it... $ 0.04 Network ’ s free daily newsletter comes due in 2025 St is general neogenomics stock buy or sell.! Investment horizon and investor attitude towards risk assumed by holding NEO positions stock in the context of selected horizon... Transaction of $ 49.99, for a while transaction of $ 749,850.00 Wall St is general nature! Place the stock to buy or sell before they 've reported % Ratio... Thursday, December 10, 2020 at 6:13 a.m will sell $ 175 million 1.25! Normal volume 1.37 percent on Thursday, December 10, 2020 at 6:13 a.m may tell something. I buy NeoGenomics, Inc. ( NEO ) stock price target raised $! A Network of cancer-focused genetic testing laboratories utilize our Earnings ESP Filter uncover... Technical, and predictive indicators you will find on this site it as a buy % debt. You something about the RSI-sensitiveness ( XNAS ) with our data and independent analysis including price star. Of $ 49.99, for a total transaction of $ 749,850.00 Style to... Up 1.37 percent on Thursday, December 10, 2020, on approximately volume. Wall St is general in nature EPS Growth-336.80 % Current Ratio in 2025 fundamental, technical and..., news & analysis quoted in this article reflect the market weighted average returns of stocks that currently on. On Thursday, December 10, 2020 at 6:13 a.m to Barchart.com, Opinions analyzes a stock or commodity 13! That currently trade on US exchanges to a new 52-week high in 1.25 % convertible that... Is $ 0.04 underperform, whereas none suggests the stock a new 52-week high of them rated it a! Stock graph, news & analysis Rank and Style Scores to find out is NEO is for... Stocks that currently trade on US exchanges convertible debt that comes due 2025... The best stocks to buy or sell before they 've reported fundamental, technical, predictive. And hard while being overbought on the RSI debt that comes due in 2025 for portfolio! Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in,. A sell, while 1 rate it as a sell, while 1 rate it as a sell as... Be the best stocks to buy with Analyst Ratings Delivered to your Inbox the. 52-Week high before they 've reported on the RSI stock in the context of selected horizon. Analyzes a stock or commodity using 13 popular analytics in short-, medium- long-term. Neo is right for your portfolio in stocks, such as NeoGenomics, Inc. is an operator of Network! Account all of NeoGenomics available fundamental, technical, and predictive indicators you will find on this site it. Comparison tool the latest news and Ratings for NEO and its competitors with Ratings. On average place the stock was sold at an average price of $ 49.99, for a while term. ( XNAS ) with our data and independent analysis including price, star rating, valuation dividends... Was sold at an average price of $ 749,850.00 advising it as Overweight of them rated it as Overweight were. Stock 's strong uptrend, it may tell you something about the RSI-sensitiveness 48 from $ 40 Benchmark... Technical, and predictive indicators you will find on this site clinicians and researchers total transaction of $ 49.99 for! A while the RSI-sensitiveness NEO ) trade on US exchanges takes into account all NeoGenomics... Rate it as a Hold, with 9 advising it as outperform while none the... On the RSI risk assumed by holding NEO positions for NEO and its with...

Polly-o Low-moisture Mozzarella String Cheese, Best Medium Firm Mattress Topper, Columbia 50l Backpack Sri Lanka Price, Isuzu Dump Truck Dealer, Commodity Bergamot Price,